No Level 4 CDC Travel Health Notices currently exist as of early June 2026, with official monitoring confirming zero destinations at the “Avoid All Travel” threshold reserved for extreme health risks lacking effective precautions. Sustained measles transmission and Level 3 Ebola notices in the DRC and Uganda demonstrate agency escalation criteria, yet fall short of Level 4 requirements tied to uncontrolled outbreaks with no mitigations. Recent vector-borne updates, including chikungunya and malaria notices at Level 2, further reflect measured surveillance responses rather than rapid intensification. With six months remaining, trader consensus at 76.5% for “No” reflects the high evidentiary bar for Level 4 issuance, absent novel high-fatality pathogens or widespread breakdowns in containment that historical patterns show are infrequent outside global-scale events.
Résumé expérimental généré par IA à partir des données Polymarket. Ceci n'est pas un conseil de trading et ne joue aucun rôle dans la résolution de ce marché. · Mis à jourLe CDC émet un avertissement de niveau 4 d'ici le 31 décembre ?
Le CDC émet un avertissement de niveau 4 d'ici le 31 décembre ?
Oui
$71,851 Vol.
$71,851 Vol.
31 déc. 2026
Oui
$71,851 Vol.
$71,851 Vol.
31 déc. 2026
This market will resolve to "Yes" if the CDC issues a Level 4 (“Avoid All Travel”) Travel Health Notice for any disease by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A Level 4 notice listed for any amount of time during this market’s timeframe will suffice for a "Yes" resolution.
The primary resolution source for this market will be the CDC’s official Travel Health Notices page (https://wwwnc.cdc.gov/travel/notices); however, a consensus of credible reporting will also be used.No Level 4 CDC Travel Health Notices currently exist as of early June 2026, with official monitoring confirming zero destinations at the “Avoid All Travel” threshold reserved for extreme health risks lacking effective precautions. Sustained measles transmission and Level 3 Ebola notices in the DRC and Uganda demonstrate agency escalation criteria, yet fall short of Level 4 requirements tied to uncontrolled outbreaks with no mitigations. Recent vector-borne updates, including chikungunya and malaria notices at Level 2, further reflect measured surveillance responses rather than rapid intensification. With six months remaining, trader consensus at 76.5% for “No” reflects the high evidentiary bar for Level 4 issuance, absent novel high-fatality pathogens or widespread breakdowns in containment that historical patterns show are infrequent outside global-scale events.
This market will resolve to "Yes" if the CDC issues a Level 4 (“Avoid All Travel”) Travel Health Notice for any disease by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A Level 4 notice listed for any amount of time during this market’s timeframe will suffice for a "Yes" resolution.
The primary resolution source for this market will be the CDC’s official Travel Health Notices page (https://wwwnc.cdc.gov/travel/notices); however, a consensus of credible reporting will also be used.
A Level 4 notice listed for any amount of time during this market’s timeframe will suffice for a "Yes" resolution.
The primary resolution source for this market will be the CDC’s official Travel Health Notices page (https://wwwnc.cdc.gov/travel/notices); however, a consensus of credible reporting will also be used.
Marché ouvert : Jan 19, 2026, 3:15 PM ET
Volume
$71,851Date de fin
31 déc. 2026Marché ouvert
Jan 19, 2026, 3:15 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if the CDC issues a Level 4 (“Avoid All Travel”) Travel Health Notice for any disease by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A Level 4 notice listed for any amount of time during this market’s timeframe will suffice for a "Yes" resolution.
The primary resolution source for this market will be the CDC’s official Travel Health Notices page (https://wwwnc.cdc.gov/travel/notices); however, a consensus of credible reporting will also be used.No Level 4 CDC Travel Health Notices currently exist as of early June 2026, with official monitoring confirming zero destinations at the “Avoid All Travel” threshold reserved for extreme health risks lacking effective precautions. Sustained measles transmission and Level 3 Ebola notices in the DRC and Uganda demonstrate agency escalation criteria, yet fall short of Level 4 requirements tied to uncontrolled outbreaks with no mitigations. Recent vector-borne updates, including chikungunya and malaria notices at Level 2, further reflect measured surveillance responses rather than rapid intensification. With six months remaining, trader consensus at 76.5% for “No” reflects the high evidentiary bar for Level 4 issuance, absent novel high-fatality pathogens or widespread breakdowns in containment that historical patterns show are infrequent outside global-scale events.
This market will resolve to "Yes" if the CDC issues a Level 4 (“Avoid All Travel”) Travel Health Notice for any disease by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A Level 4 notice listed for any amount of time during this market’s timeframe will suffice for a "Yes" resolution.
The primary resolution source for this market will be the CDC’s official Travel Health Notices page (https://wwwnc.cdc.gov/travel/notices); however, a consensus of credible reporting will also be used.
A Level 4 notice listed for any amount of time during this market’s timeframe will suffice for a "Yes" resolution.
The primary resolution source for this market will be the CDC’s official Travel Health Notices page (https://wwwnc.cdc.gov/travel/notices); however, a consensus of credible reporting will also be used.
Volume
$71,851Date de fin
31 déc. 2026Marché ouvert
Jan 19, 2026, 3:15 PM ETResolver
0x65070BE91...No Level 4 CDC Travel Health Notices currently exist as of early June 2026, with official monitoring confirming zero destinations at the “Avoid All Travel” threshold reserved for extreme health risks lacking effective precautions. Sustained measles transmission and Level 3 Ebola notices in the DRC and Uganda demonstrate agency escalation criteria, yet fall short of Level 4 requirements tied to uncontrolled outbreaks with no mitigations. Recent vector-borne updates, including chikungunya and malaria notices at Level 2, further reflect measured surveillance responses rather than rapid intensification. With six months remaining, trader consensus at 76.5% for “No” reflects the high evidentiary bar for Level 4 issuance, absent novel high-fatality pathogens or widespread breakdowns in containment that historical patterns show are infrequent outside global-scale events.
Résumé expérimental généré par IA à partir des données Polymarket. Ceci n'est pas un conseil de trading et ne joue aucun rôle dans la résolution de ce marché. · Mis à jour
Méfiez-vous des liens externes.
Méfiez-vous des liens externes.
Questions fréquentes